Hematopoiesis News Volume 14.01| Jan 10 2023

    By
    Jamie Kang
    -
    0
    30







    2023-01-10 | HN 14.01


    Hematopoiesis News by STEMCELL Technologies
    Vol. 14.01 – 10 January, 2023
    TOP STORY

    PD-1 Signaling Defines and Protects Leukemic Stem Cells from T Cell Receptor-Induced Cell Death in T Cell Acute Lymphoblastic Leukemia

    Using lineage tracing, limiting dilution assays, and in vivo live imaging approaches, scientists identified a rare inhibitory receptor programmed cell death 1 (PD-1)-expressing cells that resided at the apex of leukemia hierarchy for initiation and relapse in T cell acute lymphoblastic laukemia.
    [Nature Cell Biology]

    Abstract
    Webinar: Bone Marrow Skeletal Progenitors and Bone Diseases
    PUBLICATIONSRanked by the impact factor of the journal

    MYB Insufficiency Disrupts Proteostasis in Hematopoietic Stem Cells Leading to Age-Related Neoplasia

    Researchers described a model of Myb insufficiency in mice that lead in later life to myeloproliferative neoplasms, myelodysplasia, and leukemia, mirroring the age profile of equivalent human diseases.
    [Blood]

    Abstract

    Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Promotes Progression with High Risk of Richter’s Transformation

    Investigators demonstrated that tumors uniformly overexpressed PRMT5 in patients with progression to Richter’s Transformation.
    [Nature Communications]

    Full Article

    An Inflammatory State Remodels the Immune Microenvironment and Improves Risk Stratification in Acute Myeloid Leukemia

    Researchers provided a comprehensive census of the bone marrow immune microenvironment in adult and pediatric patients with AML.
    [Nature Cancer]

    Abstract

    Whole Bone Subcutaneous Transplantation as a Strategy to Study Precisely the Bone Marrow Niche

    Using immunolabeling of donor vs. recipient hematopoietic stem cells (HSCs), investigators demonstrated that HSCs from the host animals colonized the subcutaneously transplanted femurs after transplantation, while the HSCs from the donor disappear.
    [Stem Cell Reviews and Reports]

    Abstract

    Novel Chemical-Structure TPOR Agonist, TMEA, Promotes Megakaryocytes Differentiation and Thrombopoiesis via mTOR and ERK Signalings

    Scientists developed a novel small molecule thrombopoietin receptor (TPOR) agonist and investigated its underlying regulation of function in megakaryocytes differentiation and thrombopoiesis
    [Phytomedicine]

    AbstractGraphical Abstract

    Improved Outcomes with “7+3” Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data

    To evaluate how the length of the first complete response has changed over this time period, researchers analyzed 1,247 patients aged 65 or younger randomized to “7+3” arms from five SWOG studies.
    [Haematologica]

    Full Article

    Comorbidities in Recipients of Low Transplant Conditioning Intensity Regimens for Acute Myeloid Leukemia: An ALWP EBMT Study

    Investigators determined the contribution of individual comorbidities and their cumulative burden on the risk of non-relapse mortality in patients receiving low-intensity regimens in allogeneic-hematopoietic stem cell transplantation.
    [Blood Advances]

    Abstract

    Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease

    Scientists reported the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease.
    [Journal Of Clinical Oncology]

    Abstract
    Activate, expand, and differentiate your cells with cytokines, chemokines, and growth factors from STEMCELL Technologies.
    REVIEWS

    Inhibitory Effects and Molecular Mechanisms of Ginsenoside Rg1 on the Senescence of Hematopoietic Stem Cells

    The authors reviewed recent advances of Rg1 in inhibiting the senescence of HSCs and discussed related molecular mechanisms.
    [Fundamental & Clinical Pharmacology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

    Orchard Therapeutics announced the US FDA has cleared its Investigational New Drug (IND) application for OTL-203, a hematopoietic stem cell gene therapy being developed for the treatment of the Hurler subtype of mucopolysaccharidosis type I (MPS-IH).
    [Orchard Therapeutics]

    Press Release
    FEATURED EVENT

    Organoids as Models of Development and Disease, and Their Impact on Drug Discovery

    February 5 – 8, 2023
    Keystone, Colorado, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate Positions – Neuroscience and Biomedical research

    Upstate Medical University – Syracuse, New York, United States

    Research Scientist – Cancer Molecular Imaging

    Stanford Medicine – Stanford, California, United States

    Postdoctoral Position – Blood Cancer Institute

    Albert Einstein College of Medicine – Bronx, New York, United States

    Principal Investigator – Division of Cellular and Gene Therapies

    US FDA – Silver Spring, Maryland, United States

    Senior Program Associate – Science in the City

    STEMCELL Technologies, Inc. – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter